2025-12-19 - Analysis Report
Okay, here's a breakdown and analysis of the Procter & Gamble (PG) data provided, followed by a comprehensive summary.

**1) Return Rate Comparison and Alpha/Beta Analysis**

*   **Company Overview:** Procter & Gamble Co. is a multinational consumer goods corporation that manufactures and markets a wide range of branded products.
*   **PG Cumulative Return:** 27.06%
*   **S&P 500 (VOO) Cumulative Return:** 99.09%
*   **Divergence:** -73.0 (Relative Divergence: 7.0)

**Analysis:**  PG has significantly underperformed the S&P 500 over the period examined. The large negative divergence (-73.0) indicates a substantial difference in cumulative returns. The relative divergence of 7.0 suggests that this level of underperformance is near the lower end of its historical range.

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
|------------|---------|-------|--------|------|--------|
| 2015-2017  | 21.0%   | 7.9%  | -8.0%  | 0.0  | 215.0  |
| 2016-2018  | 9.0%    | 67.3% | -6.0%  | 0.1  | 215.1  |
| 2017-2019  | 24.0%   | 70.4% | 2.0%   | 0.3  | 292.3  |
| 2018-2020  | 27.0%   | 78.8% | 4.0%   | 0.4  | 325.7  |
| 2019-2021  | 41.0%   | 78.8% | -5.0%  | 0.5  | 382.9  |
| 2020-2022  | 13.0%   | 79.4% | 13.0%  | 0.6  | 354.7  |
| 2021-2023  | 26.0%   | 79.4% | 24.0%  | 0.4  | 343.0  |
| 2022-2024  | 9.0%    | 79.4% | -12.0% | 0.4  | 392.4  |
| 2023-2025  | -17.0%  | 80.1% | -81.0% | 0.1  | 340.6  |

**Analysis of Alpha, Beta, and other analysis:**

*   **CAGR:**  The Compound Annual Growth Rate varies significantly across the periods, with a sharp decline in the most recent period (2023-2025).
*   **MDD:** Maximum Drawdown is high across the periods, especially recent periods.
*   **Alpha:**  Alpha measures the stock's performance relative to its benchmark (risk-adjusted outperformance).  The alpha is highly volatile, with significantly negative results in recent periods (2022-2025). A highly negative Alpha of -81% for 2023-2025 indicates significant underperformance relative to the risk-free rate.
*   **Beta:** Beta is a measure of the volatility, or systematic risk, of a security or portfolio in comparison to the market as a whole. The beta values are relatively low, indicating that PG is generally less volatile than the overall market.
*   **Cap(B):** Market capitalization fluctuates but is generally high, showing that PG is a large-cap company.

**2) Recent Stock Price Fluctuations**

*   **Close:** 145.52
*   **Previous Close:** 147.81
*   **Change:** -1.55
*   **5-day SMA:** 145.30
*   **20-day SMA:** 145.09
*   **60-day SMA:** 148.19

**Analysis:** The stock closed lower than its previous close. The 5-day and 20-day Simple Moving Averages (SMAs) are below the 60-day SMA, suggesting a potential short-term downtrend. The current price is slightly below both the 5-day and 20-day SMA, indicating a near-term downward pressure on the stock.

**3) RSI, PPO Index Indicators, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 44.40
*   **PPO:** 0.36
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (7 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 5.8 (+) (단기상승 - short-term increase)
*   **Price Change Analysis:** {'price': 145.52, 'previousClose': 147.81, 'change': -1.55} - Suggests a fluctuation issue, specifically a decline.
*   **Expected Return (%):** 2.2% (Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.)

**Analysis:**

*   The MRI suggests a medium investment recommendation.
*   The RSI is at 44.4, indicating that the stock is neither overbought nor oversold.
*   The PPO is slightly positive, suggesting a potential upward trend, but it's a weak signal.
*   Hybrid signal suggests an all-in position based on "Very Safe" (MRI:0.90).
*   The recent relative divergence change (+5.8) indicates a short-term upward trend in relative performance *compared to its own historical divergence*.
*   The expected return of 2.2% is modest, indicating that analysts do not anticipate significant outperformance relative to S&P 500.

**4) Recent News & Significant Events**

*   **Analyst Downgrades & Price Target Cuts:** JPMorgan cut the price target on PG, and MarketBeat reported a downgrade, negatively impacting the stock price.
*   **Market Underperformance:** Nasdaq reports that PG stock sank as the market gained, highlighting recent underperformance.
*   **Cramer's Portfolio Pick:** Jim Cramer identified PG as a favorite portfolio stock, potentially providing a positive counterpoint to the negative news.
*   **Comparison to Competitors:** Forbes suggests considering PG over Colgate-Palmolive.
*   **2-Year Low:** Investopedia reported that PG stock hit a 2-year low, signaling significant recent weakness.

**Analysis:** Recent news is mixed, with analyst downgrades and a 2-year low creating negative sentiment. However, Cramer's positive commentary and the comparison to Colgate-Palmolive provide some potential offsetting factors.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.92)
*   **Opinions:** 22
*   **Target Price (avg/high/low):** 169.18 / 186.00 / 148.00
*   **Recent Rating Changes:** Not Available

**Analysis:** While the analyst consensus is "Buy," the recent news of downgrades suggests a potential shift in sentiment. The average target price of $169.18 indicates a potential upside from the current price, but the low target of $148 is very close to the current price, indicating significant disagreement among analysts.

**5) Recent Earnings Analysis**

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2025-10-24 | 2    | 22.39 B$    |
| 2025-04-24 | 1.58 | 19.78 B$    |
| 2025-01-22 | 1.94 | 21.88 B$    |
| 2024-10-18 | 1.65 | 21.74 B$    |
| 2025-10-24 | 1.65 | 21.74 B$    |

**Analysis:** Revenue and EPS appear to be fluctuating, with a recent EPS showing growth. However, it's important to note a duplicate entry for 2025-10-24 (likely a data error that must be fixed to allow comprehensive data analysis.).

**6) Financial Information**

Revenue and Profitability:

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-09-30 | $22.39B    | 51.37%        |
| 2025-06-30 | $20.89B    | 49.11%        |
| 2025-03-31 | $19.78B    | 50.98%        |
| 2024-12-31 | $21.88B    | 52.39%        |
| 2024-09-30 | $21.74B    | 52.06%        |

Capital and Profitability:

| Quarter    | Equity     | ROE    |
|------------|------------|--------|
| 2025-09-30 | $53.27B    | 8.92%  |
| 2025-06-30 | $52.01B    | 6.95%  |
| 2025-03-31 | $52.27B    | 7.21%  |
| 2024-12-31 | $51.17B    | 9.05%  |
| 2024-09-30 | $51.84B    | 7.64%  |

**Analysis:**

*   **Revenue:** Revenue shows some volatility across the quarters.
*   **Profit Margin:** Profit margins have been relatively stable, mostly in the 50-52% range, indicating good cost control.
*   **Equity:** Equity has increased over the last 5 quarters.
*   **ROE:** Return on Equity (ROE) fluctuates, indicating varying levels of profitability relative to shareholders' equity.

**7) Comprehensive Analysis (Summary)**

PG has significantly underperformed the S&P 500.  Recent price action shows a downtrend, with the stock trading below its 60-day SMA. Analyst sentiment is mixed, with a consensus "Buy" rating offset by recent downgrades and price target cuts.  While revenue and profit margins are relatively stable, ROE fluctuates.  News headlines are a mix of negative (downgrades, 2-year low) and positive (Cramer's pick, competitor comparison). The recent MRI shows a medium-risk investment, while the technical indicators show a downward correction. The high MDD may indicate high risk.

**Overall Recommendation:**

A cautious approach is warranted. While the analyst consensus is "Buy," the recent negative news and underperformance relative to the S&P 500 are concerning. Investors should carefully weigh the risks and potential rewards before investing.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.